Entelos, Inc. (LSE: ENTL) announced today that is has entered into a joint development and licensing agreement with Conopco Inc. d/b/a Unilever (“Unilever”).

Under this collaboration, the companies will be working closely to take advantage of Entelos’ proprietary Physiolab® platform technology to enhance Unilever’s R&D pipeline. The Physiolab platform developed during this collaboration will complement Unilever’s internal capabilities and create a powerful integrated discovery platform to accelerate Unilever’s product development. Entelos will receive an upfront payment, license fees, and milestones payments and will retain rights to use the technology outside of Unilever’s fields of interest and to build similar platforms independently of Unilever.

"This new collaboration with Unilever demonstrates the power of Entelos’ PhysioLab technology to span applications across the health and personal care spectrum," stated James Karis, President and CEO of Entelos. "We are pleased to continue working with Unilever to bring our innovative simulation technology to the forefront of research in the consumer products industry.”

“I am very excited about this collaboration. We believe systems biology can have a significant impact on our program. By partnering with leading edge companies such as Entelos we leverage the best that the external world has to offer into our research & development efforts,” stated John Weir, VP Research HPC, Unilever.

Notes to Editors

About Entelos

Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines and health-care related consumer products are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, “virtual patients”, and toxicology reference systems to develop safer and more effective drugs for pharmaceutical R&D, and to help improve the quality of health-care related consumer products. Entelos provides customized technology and research services to global pharmaceutical, health-care, and consumer products companies in arthritis, cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, skin sensitization, and personal care. The Company is also developing a model in oncology and is collaborating with the FDA to build a model of drug-induced liver injury. Entelos also offers cost-effective drug development capabilities through its strategic alliance with India-based Jubilant Biosys Ltd.

About Unilever

Unilever’s mission is to add vitality to life. We meet everyday needs for nutrition, hygiene and personal care with brands that help people feel good, look good and get more out of life. Unilever is one of the world’s leading suppliers of fast moving consumer goods with strong local roots in more than 100 countries across the globe. Its portfolio includes some of the world’s best known and most loved brands including twelve €1 billion brands and global leadership in many categories in which the company operates. The portfolio features brand icons such as: Knorr, Hellman’s, and Bertolli; Dove and Pond’s; Surf; Marmite and Pot Noodle. Unilever has around 174,000 employees in approaching 100 countries and generated annual sales of over €40 billion in 2007. For more information about Unilever and its brands, please visit www.unilever.com.

  www.entelos.com/newsReleases.php?ID=press120